ASH 2013: Emergent's otlertuzumab maintains ORR lead in Phase II
This article was originally published in Scrip
Executive Summary
Updated Phase II results for otlertuzumab from Emergent BioSolutions plus Teva Pharmaceutical's Treanda (bendamustine), which were presented at the American Society of Hematologists (ASH) Annual Meeting on 8 December, show that the CD37-targeting monoclonal antibody is maintaining its lead over Treanda alone.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.